


Beyond Ann Arbor . . .

- *X*: is used if the largest deposit is >10 cm large ("bulky disease"), or whether the mediastinum is wider than $1/3$ of the chest on a chest X-ray.
- *S*: is used if the disease has spread to the spleen



Beyond Ann Arbor . . .



Imaging and Tumor Biology

understanding response to therapy

Used to evaluate *efficacy of a novel therapy* in a clinical trial

Used to determine *treatment decisions* for an individual patient

Used for *correlative analysis* to develop predictive *tissue biomarkers*

How close are we to incorporating measurements of bulk disease in the staging system ?

- Limitations of our current staging and general anatomic response criteria
- Introduce computational / quantitative technology which may address these limitations
- What other groups have done to modify standard response assessment techniques
- How can we possibly do this
- *Focus on the biomarker and computational imaging techniques*